Directory

Cancer

Sponsored

Cancer cells possess a broad spectrum of migration and invasion mechanisms. These include both individual and collective cell-migration strategies.

Cancer therapeutics that are designed to target adhesion receptors or proteases have not proven to be effective in slowing tumour progression in clinical trials--this might be due to the fact that cancer cells can modify their migration mechanisms in response to different conditions.

view in full page

Each specific type of cancer has its own set of treatment methods.
However, many cases of cancer are treated using chemotherapy (powerful cancer-killing medication) and radiotherapy (the controlled use of high energy X-rays). Surgery is also sometimes carried out to remove cancerous tissue.

view in full page

What drives cancer cells to grow and divide uncontrollably and to escape cell death? Studies of mutations in tumor suppressor genes have provided key answers to this question.

Tumor suppressor genes often function to restrain inappropriate cell growth and division, as well as to stimulate cell death to keep our cells in proper balance. In addition, some of these genes are involved in DNA repair processes, which help prevent the accumulation of mutations in cancer-related genes.

In this way, tumor suppressor genes act as "brakes" to stop cells in their tracks before they can take the road to cancer. Given this situation, loss of tumor suppressor gene function can be disastrous, and it often puts once-normal cells on the fast track to disease.

view in full page

Whitfield practices in Boston, USA at the Massachusetts General Hospital and lectures at Harvard Medical School.

His interest include: gynecologic oncology, invasive robotic assisted & laparoscopic surgical techniques, personalized therapy for gynecologic cancers, clinical trial design and translational research into rare gynaecology cancers.

view in full page
joined 12 years, 9 months ago

Robert Leonard

Consultant Oncologist

Robert Leonard is a medical oncologist with a major interest in the management of breast cancer. He is a former Professor of Cancer Studies at Imperial College London and honorary consultant medical oncologist at Imperial College NHS Trust; The BUPA Cromwell Hospital, The London Clinic and the London Oncology Clinic. His academic roles have included 25 years in senior Academic and NHS administrative roles in London, Edinburgh and Swansea.

Professor Leonard originally trained and qualified at Charing Cross Hospital, where he was awarded the Clinical Gold Medal and six of the final year prizes. Research Fellowships at Oxford’s Radcliffe Infirmary and Harvard Medical School followed his post-graduate training.

Prior to his roles as Professor of Cancer Studies and Chief of Service for Medical Oncology at Imperial College, he was Professor of Medical Oncology at Swansea Medical School and Director of the South West Wales Cancer Institute.

He is a co-founder and is Medical Director for Maggies’ Cancer Caring Centres UK, and chairs the professional advisory board. Since 2009 he has been Chair of the Scientific Board for Breast Cancer Care UK. He set up and Chairs the International Anglo Celtic Collaborative Oncology Trials Group.

He is author/co-author of more than 350 peer reviewed original papers and reviews. He has been a senior advisor to Cancer Research UK and is lead investigator several previous and current UK clinical Trials. He also regularly acts as expert oncology witness for legal cases.

 


view this profile
joined 12 years, 9 months ago

Karol Sikora

Professor, Cancer Expert

Professor Sikora is a British physician specialising in oncology. He is medical director of Rutherford Health, and Director of Medical Oncology at the Bahamas Cancer Centre. He is also Professor of Medicine at the University of Buckingham, and a partner in and dean of Buckingham's medical school.

Professor Sikora studied medical science and biochemistry at Cambridge, where he obtained a double first.

After clinical training he became a house physician at The Middlesex Hospital and registrar in oncology at St Bartholomew’s Hospital. He later became a research student at the MRC Laboratory for Molecular Biology in Cambridge working with Nobel Prize winner, Dr Sydney Brenner.

He obtained his PhD and became a clinical fellow at Stanford University, California before returning to direct the Ludwig Institute in Cambridge.

He has been Clinical Director for Cancer Services at Hammersmith for 12 years and established a major cancer research laboratory there funded by the Imperial Cancer Research Fund. He chaired Help Hammer Cancer, an appeal that raised £8m towards the construction of the new Cancer Centre at Hammersmith. He became Deputy Director (Clinical Research) of the ICRF.From 1997 to 1999 he was Chief of the WHO Cancer Program and from 1999 to 2002 and Vice President, Global Clinical Research (Oncology) at Pharmacia Corporation.

He has published over 300 papers and written or edited 20 books and is on the editorial board of several journals and is the founding editor of Gene Therapy and Cancer Strategy.

He was a member of the UK Health Department’s Expert Advisory Group on Cancer (the Calman-Hine Committee), the Committee on Safety of Medicines and remains an adviser to the WHO. He currently directs a cancer drug donation programme in Africa.

 


view this profile
joined 12 years, 9 months ago

John Green

Senior Lecturer in Medical Oncology at University of Liverpool

John Green is a leading internationally recognised oncologist specializing in gynaecologic and ovarian cancers.


view this profile
joined 12 years, 9 months ago

Hani Gabra

Co-Founder, Board Member and Chief Scientific Officer at Papyrus Therapeutics Inc; Consultant Medical Oncologist, Portsmouth Hospitals University NHS Trust; Professor Emeritus in Medical Oncology, Imperial College London

Professor Gabra is Co-Founder, Board Member and Chief Scientific Officer at Papyrus Therapeutics Inc; he also hold the position of Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust and is Professor Emeritus in Medical Oncology, Imperial College London.

He has extensive experience of preclinical cancer biology and clinical drug development, having previously been Chief Medical Officer at BerGenBio,Oxford, UK and Vice President in Early Clinical Development at AstraZeneca in Cambridge, UK, concurrently holding the positions of Professor of Medical Oncology at Imperial College London and Honorary Consultant in Medical Oncology at Imperial College Healthcare NHS Trust (since 2003) and Adjunct Professor at the Centre for Cancer Biomarkers at University of Bergen. He was previously Head of Medical Oncology, Director of the Ovarian Cancer Action Research Centre and Head of Imperial College Cancer Clinical Trials Unit, as well as Chief of Service of the West London Gynaecological Cancer Centre at Imperial College London. Prior to that he was Cancer Research UK Clinical Scientist and Honorary Clinical Senior Lecturer/Consultant in Medical Oncology at the CRUK Medical Oncology Unit in the University of Edinburgh.

Prof Gabra is an internationally recognised leader in translational research and gynaecological oncology. His research interests include tumour suppressor genes that regulate receptor tyrosine kinase networks (including AXL), the molecular basis of clinical platinum resistance, and all phases of ovarian cancer clinical research. He is the author of more than 200 peer reviewed publications and patents, with over 15,000 citations associated with his publications.

 .


view this profile